Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Bayer AG. (9/17/19). "Press Release: Bayer and Informed Data Systems Inc. to Develop One Drop Digital Therapeutics Platform for Multiple Therapeutic Areas [Not intended for U.S. and UK Media]". Berlin.

Organisations Organisation Bayer Pharma AG
  Group Bayer (Group)
  Organisation 2 Informed Data Systems Inc.
Products Product One Drop digital therapeutics platform
  Product 2 digital health (healthcare informatics)
Index terms Index term Bayer–Informed Data Systems: digital health, 201909– collab + licensing agreem $10m developm + commercialisaing of One Drop technology platform
  Index term 2 Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer
Persons Person Oelrich, Stefan (Bayer 201811– Head of Pharma division before Sanofi Head of Diabetes + Cardiovascular)
  Person 2 Dachis, Jeffrey A. (Jeff) (Informed Data Systems 201909 CEO + Founder)

Equity stake in company through Series B financing of USD 20 million acquired / USD 10 million commercial licensing agreement for One Drop digital platform signed

Bayer and Informed Data Systems Inc., a US-based digital health company, have entered into a collaboration and licensing agreement to leverage Informed Data Systems’ One Drop digital therapeutics platform to provide integrated solutions and services in multiple therapeutic areas empowering people with chronic diseases to aim at better outcomes.

One Drop offers a digital self-management platform to improve health outcomes. Bayer is investing USD 20 million in a Series B financing in the company and has signed a licensing agreement worth USD 10 million for developing and commercializing the One Drop technology platform further.

“As part of our strategy to shape the future of healthcare and build new businesses in digital health, we are investing in integrated digital solutions to improve health outcomes through data driven solutions”, said Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals. “This collaboration allows us to obtain access to a world leading self-care platform for disease management beyond the boundaries of medicines with strong artificial intelligence-driven capabilities that could lead to better healthcare outcomes for people with chronic conditions.”

One Drop is an evidence-based and clinically proven innovative digital therapeutic platform through the use of an integrated patient facing application, monitor and coaching/behavioral change programs. Originally developed for diabetes management, this platform will support Bayer in building Integrated Care patient services offerings.

“With demographic shifts causing an increase in chronic diseases and multiple conditions, and with public health systems already facing cost pressures, data-driven, digital technology is transforming how patients access quality healthcare more effectively and at a lower cost,” said Jeff Dachis, Informed Data Systems’ Founder and CEO. “We are looking forward to partnering with Bayer to help patients worldwide manage conditions like cancer and heart disease.”

About Informed Data Systems Inc.

Informed Data Systems Inc. is a digital health company harnessing the power of mobile computing and data science to transform the lives of people with diabetes worldwide. Its One Drop platform brings affordable, accessible diabetes care to everyone with diabetes and a smartphone, as well as their employers, insurers and health care providers.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to

Find more information at
Our online press service is just a click away:
Follow us on Facebook:
Follow us on Twitter: @BayerPharma

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Bayer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top